TSC1 and lymphangioleiomyomatosis: This research highlights a new potential area to develop for LAM treatments and combination immunotherapies, and has promising implications for the use of CpG-ODN as an adjuvant in the development of vaccines against LAM specific antigens when reliable markers for these disease cells can be identified.